Vis enkel innførsel

dc.contributor.authorReutfors, Johan
dc.contributor.authorCesta, Carolyn
dc.contributor.authorCohen, Jacqueline Mallory
dc.contributor.authorBateman, Brian T
dc.contributor.authorBrauer, Ruth
dc.contributor.authorEinarsdottir, Kristjana
dc.contributor.authorEngeland, Anders
dc.contributor.authorFuru, Kari
dc.contributor.authorGissler, Mika
dc.contributor.authorHavard, Alys
dc.contributor.authorHernandez-Diaz, Sonia
dc.contributor.authorHuybrechts, Krista F.
dc.contributor.authorKarlstad, Øystein
dc.contributor.authorLeinonen, Maarit
dc.contributor.authorLi, Jiong
dc.contributor.authorMan, Kenneth K. C.
dc.contributor.authorPazzagli, Laura
dc.contributor.authorSchaffer, Andrea
dc.contributor.authorSchink, Tania
dc.contributor.authorWang, Zixuan
dc.contributor.authorYu, Yongfu
dc.contributor.authorZoega, Helga
dc.contributor.authorBröms, Gabriella
dc.date.accessioned2021-04-23T13:05:20Z
dc.date.available2021-04-23T13:05:20Z
dc.date.created2020-09-22T13:42:05Z
dc.date.issued2020
dc.PublishedSchizophrenia Research. 2020, 220 (June), 106-115.
dc.identifier.issn0920-9964
dc.identifier.urihttps://hdl.handle.net/11250/2739380
dc.description.abstractAim To compare the prevalence and trends of antipsychotic drug use during pregnancy between countries across four continents. Methods Individually linked health data in Denmark (2000−2012), Finland (2005–2014), Iceland (2004–2017), Norway (2005–2015), Sweden (2006–2015), Germany (2006–2015), Australia (New South Wales, 2004–2012), Hong Kong (2001–2015), UK (2006–2016), and the US (Medicaid, 2000–2013, and IBM MarketScan, 2012–2015) were used. Using a uniformed approach, we estimated the prevalence of antipsychotic use as the proportion of pregnancies where a woman filled at least one antipsychotic prescription within three months before pregnancy until birth. For the Nordic countries, data were meta-analyzed to investigate maternal characteristics associated with the use of antipsychotics. Results We included 8,394,343 pregnancies. Typical antipsychotic use was highest in the UK (4.4%) whereas atypical antipsychotic use was highest in the US Medicaid (1.5%). Atypical antipsychotic use increased over time in most populations, reaching 2% in Australia (2012) and US Medicaid (2013). In most countries, prochlorperazine was the most commonly used typical antipsychotic and quetiapine the most commonly used atypical antipsychotic. Use of antipsychotics decreased across the trimesters of pregnancy in all populations except Finland. Antipsychotic use was elevated among smokers and those with parity ≥4 in the Nordic countries. Conclusion Antipsychotic use during pregnancy varied considerably between populations, partly explained by varying use of the typical antipsychotic prochlorperazine, which is often used for nausea and vomiting in early pregnancy. Increasing usage of atypical antipsychotics among pregnant women reflects the pattern that was previously reported for the general population.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S0920996420301584
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleAntipsychotic drug use in pregnancy: A multinational study from ten countriesen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2020 The Authorsen_US
cristin.ispublishedfalse
cristin.fulltextpostprint
cristin.qualitycode2
dc.identifier.doi10.1016/j.schres.2020.03.048
dc.identifier.cristin1832124
dc.source.journalSchizophrenia Researchen_US
dc.source.40220
dc.source.14June
dc.source.pagenumber106-115en_US
dc.identifier.citationSchizophrenia Research. 2020, 220: 106-115en_US
dc.source.volume220en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal